Lidocaine Patches May Enable Safer Oral Gabapentin Use

In more than half of patients with neuropathic pain (NP), first-line pharmaceutical monotherapies like gabapentin fail to deliver adequate pain relief. This has led to the use of combination systemic therapy that carries the risk for drug–drug interactions and related adverse events (AEs). Data published in Pain and Therapy (2025 Jun. doi:10.1007/s40122-025-00733-7) indicate that adding lidocaine patches to oral gabapentin therapy for NP can improve patient outcomes with a lower risk for